{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,6]],"date-time":"2026-11-06T01:11:30Z","timestamp":1793927490957,"version":"4.8.0"},"reference-count":92,"publisher":"Oxford University Press (OUP)","issue":"25","license":[{"start":{"date-parts":[[2023,5,2]],"date-time":"2023-05-02T00:00:00Z","timestamp":1682985600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2023,7,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>This 2023 statement updates clinical guidance for homozygous familial hypercholesterolaemia (HoFH), explains the genetic complexity, and provides pragmatic recommendations to address inequities in HoFH care worldwide. Key strengths include updated criteria for the clinical diagnosis of HoFH and the recommendation to prioritize phenotypic features over genotype. Thus, a low-density lipoprotein cholesterol (LDL-C) &amp;gt;10 mmol\/L (&amp;gt;400 mg\/dL) is suggestive of HoFH and warrants further evaluation. The statement also provides state-of-the art discussion and guidance to clinicians for interpreting the results of genetic testing and for family planning and pregnancy. Therapeutic decisions are based on the LDL-C level. Combination LDL-C-lowering therapy\u2014both pharmacologic intervention and lipoprotein apheresis (LA)\u2014is foundational. Addition of novel, efficacious therapies (i.e. inhibitors of proprotein convertase subtilisin\/kexin type 9, followed by evinacumab and\/or lomitapide) offers potential to attain LDL-C goal or reduce the need for LA. To improve HoFH care around the world, the statement recommends the creation of national screening programmes, education to improve awareness, and management guidelines that account for the local realities of care, including access to specialist centres, treatments, and cost. This updated statement provides guidance that is crucial to early diagnosis, better care, and improved cardiovascular health for patients with HoFH worldwide.<\/jats:p>","DOI":"10.1093\/eurheartj\/ehad197","type":"journal-article","created":{"date-parts":[[2023,3,21]],"date-time":"2023-03-21T20:17:19Z","timestamp":1679429839000},"page":"2277-2291","source":"Crossref","is-referenced-by-count":358,"title":["2023 Update on European Atherosclerosis Society Consensus Statement on Homozygous Familial Hypercholesterolaemia: new treatments and clinical guidance"],"prefix":"10.1093","volume":"44","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-6808-3824","authenticated-orcid":false,"given":"Marina","family":"Cuchel","sequence":"first","affiliation":[{"name":"Division of Translational Medicine and Human Genetics, Department of Medicine, Perelman School of Medicine, University of Pennsylvania , 9017 Maloney Building, 3600 Spruce Street, Philadelphia, PA 19104 , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9170-7938","authenticated-orcid":false,"given":"Frederick J","family":"Raal","sequence":"additional","affiliation":[{"name":"Carbohydrate and Lipid Metabolism Research Unit, Division of Endocrinology and Metabolism, Department of Medicine, Faculty of Health Sciences, University of the Witwatersrand Parktown , Johannesburg , South Africa"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2861-5325","authenticated-orcid":false,"given":"Robert A","family":"Hegele","sequence":"additional","affiliation":[{"name":"Department of Medicine and Robarts Research Institute, Schulich School of Medicine and Dentistry, Western University , London, Ontario , Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0460-1236","authenticated-orcid":false,"given":"Khalid","family":"Al-Rasadi","sequence":"additional","affiliation":[{"name":"Department of Biochemistry, College of Medicine & Health Sciences, Medical Research Center, Sultan Qaboos University , Muscat , Oman"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3786-0883","authenticated-orcid":false,"given":"Marcello","family":"Arca","sequence":"additional","affiliation":[{"name":"Department of Translational and Precision Medicine, Sapienza University of Rome , Rome , Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3558-9209","authenticated-orcid":false,"given":"Maurizio","family":"Averna","sequence":"additional","affiliation":[{"name":"Department of Health Promotion Sciences Maternal and Infantile Care, Internal Medicine and Medical Specialities, University of Palermo , Palermo , Italy"},{"name":"Istituto di Biofisica, Consiglio Nazionale delle Ricerche , Genova , Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eric","family":"Bruckert","sequence":"additional","affiliation":[{"name":"Piti\u00e9-Salp\u00eatri\u00e8re Hospital and Sorbonne University, Cardio metabolic Institute , Paris , France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6532-7053","authenticated-orcid":false,"given":"Tomas","family":"Freiberger","sequence":"additional","affiliation":[{"name":"Centre for Cardiovascular Surgery and Transplantation, and Medical Faculty, Masaryk University , Brno , Czech Republic"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5185-3666","authenticated-orcid":false,"given":"Daniel","family":"Gaudet","sequence":"additional","affiliation":[{"name":"Clinical Lipidology and Rare Lipid Disorders Unit, Community Genomic Medicine Center, Department of Medicine, Universit\u00e9 de Montr\u00e9al, ECOGENE, Clinical and Translational Research Center, and Lipid Clinic, Chicoutimi Hospital , Chicoutimi, Qu\u00e9bec , Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7600-2059","authenticated-orcid":false,"given":"Mariko","family":"Harada-Shiba","sequence":"additional","affiliation":[{"name":"Cardiovascular Center, Osaka Medical and Pharmaceutical University , Osaka , Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lisa C","family":"Hudgins","sequence":"additional","affiliation":[{"name":"Rogosin Institute, Weill Cornell Medical College , New York, NY , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3692-5227","authenticated-orcid":false,"given":"Meral","family":"Kayikcioglu","sequence":"additional","affiliation":[{"name":"Department of Cardiology, Faculty of Medicine, Ege University , Izmir , Turkey"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0789-4954","authenticated-orcid":false,"given":"Luis","family":"Masana","sequence":"additional","affiliation":[{"name":"Vascular Medicine and Metabolism Unit, Research Unit on Lipids and Atherosclerosis, Sant Joan University Hospital, Universitat Rovira i Virgili, IISPV CIBERDEM , Reus , Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9873-0412","authenticated-orcid":false,"given":"Klaus G","family":"Parhofer","sequence":"additional","affiliation":[{"name":"Medizinische Klinik und Poliklinik IV, Ludwigs-Maximilians University Klinikum , Munich , Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6870-9962","authenticated-orcid":false,"given":"Jeanine E","family":"Roeters van Lennep","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, Erasmus MC, Medical Center , Rotterdam , The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9860-6582","authenticated-orcid":false,"given":"Raul D","family":"Santos","sequence":"additional","affiliation":[{"name":"Lipid Clinic, Heart Institute (InCor), University of S\u00e3o Paulo Medical School Hospital , S\u00e3o Paulo , Brazil"},{"name":"Academic Research Organization Hospital Israelita Albert Einstein , Sao Paulo , Brazil"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9555-6260","authenticated-orcid":false,"given":"Erik S G","family":"Stroes","sequence":"additional","affiliation":[{"name":"Department of Vascular Medicine, Amsterdam Cardiovascular Sciences, Amsterdam University Medical Centers, University of Amsterdam , Amsterdam , The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gerald F","family":"Watts","sequence":"additional","affiliation":[{"name":"Medical School, University of Western Australia, and Department of Cardiology, Lipid Disorders Clinic, Royal Perth Hospital , Perth , Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6223-5671","authenticated-orcid":false,"given":"Albert","family":"Wiegman","sequence":"additional","affiliation":[{"name":"Department of Pediatrics, Amsterdam University Medical Centers, University of Amsterdam , Amsterdam , The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jane K","family":"Stock","sequence":"additional","affiliation":[{"name":"European Atherosclerosis Society , Gothenburg , Sweden"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lale S","family":"Tokg\u00f6zo\u011flu","sequence":"additional","affiliation":[{"name":"Department of Cardiology, Hacettepe University Faculty of Medicine , Ankara , Turkey"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7593-2094","authenticated-orcid":false,"given":"Alberico L","family":"Catapano","sequence":"additional","affiliation":[{"name":"IRCCS MultiMedica, and Department of Pharmacological and Biomolecular Sciences, Universit\u00e0 degli Studi di Milano , Milan , Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0508-0954","authenticated-orcid":false,"given":"Kausik K","family":"Ray","sequence":"additional","affiliation":[{"name":"Imperial Centre for Cardiovascular Disease Prevention, Department of Primary Care and Public Health, School of Public Health, Imperial College London , London , UK"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2023,5,2]]},"reference":[{"key":"2023070109284495400_ehad197-B1","doi-asserted-by":"crossref","first-page":"2146","DOI":"10.1093\/eurheartj\/ehu274","article-title":"Homozygous familial hypercholesterolaemia: new insights and guidance for clinicians to improve detection and clinical management. A position paper from the Consensus Panel on Familial Hypercholesterolaemia of the European Atherosclerosis Society","volume":"35","author":"Cuchel","year":"2014","journal-title":"Eur Heart J"},{"key":"2023070109284495400_ehad197-B2","doi-asserted-by":"crossref","first-page":"128","DOI":"10.1016\/j.atherosclerosis.2016.10.017","article-title":"HEART UK statement on the management of homozygous familial hypercholesterolaemia in the United Kingdom","volume":"255","author":"France","year":"2016","journal-title":"Atherosclerosis"},{"key":"2023070109284495400_ehad197-B3","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1016\/j.ijcard.2013.11.025","article-title":"Integrated guidance on the care of familial hypercholesterolaemia from the International FH Foundation","volume":"171","author":"Watts","year":"2014","journal-title":"Int J Cardiol"},{"key":"2023070109284495400_ehad197-B4","doi-asserted-by":"crossref","first-page":"751","DOI":"10.5551\/jat.CR003","article-title":"Guidelines for diagnosis and treatment of familial hypercholesterolemia 2017","volume":"25","author":"Harada-Shiba","year":"2018","journal-title":"J Atheroscler Thromb"},{"key":"2023070109284495400_ehad197-B5","doi-asserted-by":"crossref","first-page":"1553","DOI":"10.1016\/j.cjca.2018.09.005","article-title":"Canadian Cardiovascular Society Position Statement on Familial Hypercholesterolemia: update 2018","volume":"34","author":"Brunham","year":"2018","journal-title":"Can J Cardiol"},{"key":"2023070109284495400_ehad197-B6","doi-asserted-by":"crossref","first-page":"324","DOI":"10.1016\/j.hlc.2020.09.943","article-title":"Integrated guidance for enhancing the care of familial hypercholesterolaemia in Australia","volume":"30","author":"Watts","year":"2021","journal-title":"Heart Lung Circ"},{"key":"2023070109284495400_ehad197-B7","doi-asserted-by":"crossref","first-page":"3209","DOI":"10.1093\/eurheartj\/ehac224","article-title":"Screening in children for familial hypercholesterolaemia: start now","volume":"43","author":"Groselj","year":"2022","journal-title":"Eur Heart J"},{"key":"2023070109284495400_ehad197-B8","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1001\/jamacardio.2019.5173","article-title":"Reducing the clinical and public health burden of familial hypercholesterolemia: a global call to action","volume":"5","author":"Representatives of the Global Familial Hypercholesterolemia Community","year":"2020","journal-title":"JAMA Cardiol"},{"key":"2023070109284495400_ehad197-B9","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1016\/j.atherosclerosis.2015.09.021","article-title":"Familial hypercholesterolaemia: a global call to arms","volume":"243","author":"Vallejo-Vaz","year":"2015","journal-title":"Atherosclerosis"},{"key":"2023070109284495400_ehad197-B10","doi-asserted-by":"crossref","first-page":"1742","DOI":"10.1161\/CIRCULATIONAHA.119.044795","article-title":"Prevalence of familial hypercholesterolemia among the general population and patients with atherosclerotic cardiovascular disease: a systematic review and meta-analysis","volume":"141","author":"Hu","year":"2020","journal-title":"Circulation"},{"key":"2023070109284495400_ehad197-B11","doi-asserted-by":"crossref","first-page":"2553","DOI":"10.1016\/j.jacc.2020.03.057","article-title":"Worldwide prevalence of familial hypercholesterolemia: meta-analyses of 11 million subjects","volume":"75","author":"Beheshti","year":"2020","journal-title":"J Am Coll Cardiol"},{"key":"2023070109284495400_ehad197-B12","doi-asserted-by":"crossref","first-page":"719","DOI":"10.1016\/S0140-6736(21)02001-8","article-title":"Worldwide experience of homozygous familial hypercholesterolaemia: retrospective cohort study","volume":"399","author":"Tromp","year":"2022","journal-title":"Lancet"},{"key":"2023070109284495400_ehad197-B13","doi-asserted-by":"crossref","first-page":"560","DOI":"10.1093\/eurheartj\/ehu058","article-title":"Homozygous autosomal dominant hypercholesterolaemia in The Netherlands: prevalence, genotype-phenotype relationship, and clinical outcome","volume":"36","author":"Sjouke","year":"2015","journal-title":"Eur Heart J"},{"key":"2023070109284495400_ehad197-B14","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1016\/j.atherosclerosis.2020.08.027","article-title":"Homozygous familial hypercholesterolemia in Italy: clinical and molecular features","volume":"312","author":"Bertolini","year":"2020","journal-title":"Atherosclerosis"},{"key":"2023070109284495400_ehad197-B15","doi-asserted-by":"crossref","first-page":"966","DOI":"10.1161\/01.CIR.0000116766.31036.03","article-title":"Ezetimibe effectively reduces plasma plant sterols in patients with sitosterolemia","volume":"109","author":"Salen","year":"2004","journal-title":"Circulation"},{"key":"2023070109284495400_ehad197-B16","doi-asserted-by":"crossref","first-page":"588","DOI":"10.1136\/jcp.2007.049775","article-title":"Sitosterolaemia: pathophysiology, clinical presentation and laboratory diagnosis","volume":"61","author":"Kidambi","year":"2008","journal-title":"J Clin Pathol"},{"key":"2023070109284495400_ehad197-B17","doi-asserted-by":"crossref","first-page":"162","DOI":"10.1016\/j.atherosclerosis.2014.02.030","article-title":"Premature atherosclerosis is not systematic in phytosterolemic patients: severe hypercholesterolemia as a confounding factor in five subjects","volume":"234","author":"Hansel","year":"2014","journal-title":"Atherosclerosis"},{"key":"2023070109284495400_ehad197-B18","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1016\/S2213-8587(19)30264-5","article-title":"Rare dyslipidaemias, from phenotype to genotype to management: a European Atherosclerosis Society task force consensus statement","volume":"8","author":"Hegele","year":"2020","journal-title":"Lancet Diabetes Endocrinol"},{"key":"2023070109284495400_ehad197-B19","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1097\/MOL.0b013e328362df13","article-title":"Cerebrotendinous xanthomatosis","volume":"24","author":"Bjorkhem","year":"2013","journal-title":"Curr Opin Lipidol"},{"key":"2023070109284495400_ehad197-B20","doi-asserted-by":"crossref","first-page":"905","DOI":"10.5551\/jat.RV17055","article-title":"Cerebrotendinous xanthomatosis: molecular pathogenesis, clinical spectrum, diagnosis, and disease-modifying treatments","volume":"28","author":"Koyama","year":"2021","journal-title":"J Atheroscler Thromb"},{"key":"2023070109284495400_ehad197-B21","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1038\/s41569-018-0052-6","article-title":"The complex molecular genetics of familial hypercholesterolaemia","volume":"16","author":"Berberich","year":"2019","journal-title":"Nat Rev Cardiol"},{"key":"2023070109284495400_ehad197-B22","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1097\/MOL.0000000000000664","article-title":"Autosomal recessive hypercholesterolemia: update for 2020","volume":"31","author":"D'Erasmo","year":"2020","journal-title":"Curr Opin Lipidol"},{"key":"2023070109284495400_ehad197-B23","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1016\/j.atherosclerosis.2021.03.015","article-title":"Correspondence on: \u201chomozygous familial hypercholesterolemia in Italy: clinical and molecular features\u201d","volume":"326","author":"Biesecker","year":"2021","journal-title":"Atherosclerosis"},{"key":"2023070109284495400_ehad197-B24","doi-asserted-by":"crossref","DOI":"10.1038\/nrdp.2017.93","article-title":"Familial hypercholesterolaemia","volume":"3","author":"Defesche","year":"2017","journal-title":"Nat Rev Dis Primers"},{"key":"2023070109284495400_ehad197-B25","doi-asserted-by":"crossref","first-page":"398","DOI":"10.1016\/j.jacl.2020.04.011","article-title":"Genetic testing in dyslipidemia: a scientific statement from the National Lipid Association","volume":"14","author":"Brown","year":"2020","journal-title":"J Clin Lipidol"},{"key":"2023070109284495400_ehad197-B26","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1016\/j.gim.2021.09.012","article-title":"The Clinical Genome Resource (ClinGen) Familial Hypercholesterolemia Variant Curation Expert Panel consensus guidelines for LDLR variant classification","volume":"24","author":"Chora","year":"2022","journal-title":"Genet Med"},{"key":"2023070109284495400_ehad197-B27","doi-asserted-by":"crossref","first-page":"176","DOI":"10.1097\/MOL.0000000000000686","article-title":"Evidence for improved survival with treatment of homozygous familial hypercholesterolemia","volume":"31","author":"Belanger","year":"2020","journal-title":"Curr Opin Lipidol"},{"key":"2023070109284495400_ehad197-B28","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1097\/MOL.0000000000000738","article-title":"Editorial comment: hazards of interpreting genetic reports","volume":"32","author":"Lazarte","year":"2021","journal-title":"Curr Opin Lipidol"},{"key":"2023070109284495400_ehad197-B29","doi-asserted-by":"crossref","first-page":"515","DOI":"10.1161\/CIRCGEN.120.002919","article-title":"Polygenic contribution to low-density lipoprotein cholesterol levels and cardiovascular risk in monogenic familial hypercholesterolemia","volume":"13","author":"Trinder","year":"2020","journal-title":"Circ Genom Precis Med"},{"key":"2023070109284495400_ehad197-B30","doi-asserted-by":"crossref","first-page":"2439","DOI":"10.1161\/ATVBAHA.116.308027","article-title":"Polygenic versus monogenic causes of hypercholesterolemia ascertained clinically","volume":"36","author":"Wang","year":"2016","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"2023070109284495400_ehad197-B31","article-title":"Clinical implications of monogenic versus polygenic hypercholesterolemia: long-term response to treatment, coronary atherosclerosis burden, and cardiovascular events","volume":"10","author":"D'Erasmo","year":"2021","journal-title":"J Am Heart Assoc"},{"key":"2023070109284495400_ehad197-B32","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1097\/MOL.0000000000000732","article-title":"The genetic counselor's role in management of patients with dyslipidemia","volume":"32","author":"Brown","year":"2021","journal-title":"Curr Opin Lipidol"},{"key":"2023070109284495400_ehad197-B33","doi-asserted-by":"crossref","first-page":"S213","DOI":"10.1542\/peds.2009-2107C","article-title":"Expert panel on integrated guidelines for cardiovascular health and risk reduction in children and adolescents: summary report","volume":"128","author":"Expert Panel on Integrated Guidelines for Cardiovascular Health, Risk Reduction in Children, Adolescents, National Heart Lung, Blood Institute","year":"2011","journal-title":"Pediatrics"},{"key":"2023070109284495400_ehad197-B34","author":"National Institute for Health and Care Excellence"},{"key":"2023070109284495400_ehad197-B35","doi-asserted-by":"crossref","first-page":"2425","DOI":"10.1093\/eurheartj\/ehv157","article-title":"Familial hypercholesterolaemia in children and adolescents: gaining decades of life by optimizing detection and treatment","volume":"36","author":"Wiegman","year":"2015","journal-title":"Eur Heart J"},{"key":"2023070109284495400_ehad197-B36","doi-asserted-by":"crossref","first-page":"2301","DOI":"10.1093\/eurjpc\/zwac200","article-title":"Paediatric familial hypercholesterolaemia screening in Europe\u2014public policy background and recommendations","volume":"29","author":"Gidding","year":"2022","journal-title":"Eur J Prev Cardiol"},{"key":"2023070109284495400_ehad197-B37","doi-asserted-by":"crossref","first-page":"1250","DOI":"10.1016\/j.jacc.2015.07.017","article-title":"Universal screening for familial hypercholesterolemia in children","volume":"66","author":"Klancar","year":"2015","journal-title":"J Am Coll Cardiol"},{"key":"2023070109284495400_ehad197-B38","article-title":"The time is now: achieving FH paediatric screening across Europe\u2014the Prague declaration","volume":"16","author":"Bedlington","year":"2022","journal-title":"GMS Health Innov Technol"},{"key":"2023070109284495400_ehad197-B39","doi-asserted-by":"crossref","first-page":"210","DOI":"10.1016\/j.atherosclerosis.2018.09.039","article-title":"Detecting familial hypercholesterolemia earlier in life by actively searching for affected children: the DECOPIN project","volume":"278","author":"Ibarretxe","year":"2018","journal-title":"Atherosclerosis"},{"key":"2023070109284495400_ehad197-B40","doi-asserted-by":"crossref","first-page":"3925","DOI":"10.1093\/eurheartj\/ehac361","article-title":"Lipoprotein(a) in atherosclerotic cardiovascular disease and aortic stenosis: a European Atherosclerosis Society consensus statement","volume":"43","author":"Kronenberg","year":"2022","journal-title":"Eur Heart J"},{"key":"2023070109284495400_ehad197-B41","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1016\/j.atherosclerosis.2019.04.219","article-title":"Coronary computed tomography angiography and echocardiography in children with homozygous familial hypercholesterolemia","volume":"285","author":"Luirink","year":"2019","journal-title":"Atherosclerosis"},{"key":"2023070109284495400_ehad197-B42","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1093\/eurheartj\/ehz455","article-title":"2019 ESC\/EAS guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk","volume":"41","author":"Mach","year":"2020","journal-title":"Eur Heart J"},{"key":"2023070109284495400_ehad197-B43","doi-asserted-by":"crossref","first-page":"830","DOI":"10.1093\/eurheartj\/ehab718","article-title":"Combination lipid-lowering therapy as first-line strategy in very high-risk patients","volume":"43","author":"Ray","year":"2022","journal-title":"Eur Heart J"},{"key":"2023070109284495400_ehad197-B44","doi-asserted-by":"crossref","first-page":"188","DOI":"10.1097\/MED.0000000000000590","article-title":"Novel therapies for familial hypercholesterolemia","volume":"28","author":"Mohamed","year":"2021","journal-title":"Curr Opin Endocrinol Diabetes Obes"},{"key":"2023070109284495400_ehad197-B45","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1016\/S0140-6736(14)61374-X","article-title":"Inhibition of PCSK9 with evolocumab in homozygous familial hypercholesterolaemia (TESLA part B): a randomised, double-blind, placebo-controlled trial","volume":"385","author":"Raal","year":"2015","journal-title":"Lancet"},{"key":"2023070109284495400_ehad197-B46","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1016\/j.jacc.2020.05.027","article-title":"Efficacy and safety of alirocumab in adults with homozygous familial hypercholesterolemia: the ODYSSEY HoFH trial","volume":"76","author":"Blom","year":"2020","journal-title":"J Am Coll Cardiol"},{"key":"2023070109284495400_ehad197-B47","doi-asserted-by":"crossref","first-page":"565","DOI":"10.1016\/j.jacc.2019.12.020","article-title":"Long-term evolocumab in patients with familial hypercholesterolemia","volume":"75","author":"Santos","year":"2020","journal-title":"J Am Coll Cardiol"},{"key":"2023070109284495400_ehad197-B48","doi-asserted-by":"crossref","first-page":"280","DOI":"10.1016\/S2213-8587(17)30044-X","article-title":"Long-term treatment with evolocumab added to conventional drug therapy, with or without apheresis, in patients with homozygous familial hypercholesterolaemia: an interim subset analysis of the open-label TAUSSIG study","volume":"5","author":"Raal","year":"2017","journal-title":"Lancet Diabetes Endocrinol"},{"key":"2023070109284495400_ehad197-B49","doi-asserted-by":"crossref","first-page":"2113","DOI":"10.1161\/CIRCULATIONAHA.113.004678","article-title":"Effect of the proprotein convertase subtilisin\/kexin 9 monoclonal antibody, AMG 145, in homozygous familial hypercholesterolemia","volume":"128","author":"Stein","year":"2013","journal-title":"Circulation"},{"key":"2023070109284495400_ehad197-B50","doi-asserted-by":"crossref","first-page":"652","DOI":"10.1016\/S2352-4642(21)00095-X","article-title":"Advances in familial hypercholesterolaemia in children","volume":"5","author":"Reijman","year":"2021","journal-title":"Lancet Child Adolesc Health"},{"key":"2023070109284495400_ehad197-B51","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1186\/1743-7075-9-14","article-title":"Multiple functions of microsomal triglyceride transfer protein","volume":"9","author":"Hussain","year":"2012","journal-title":"Nutr Metab (Lond)"},{"key":"2023070109284495400_ehad197-B52","doi-asserted-by":"crossref","first-page":"1200","DOI":"10.1007\/s12325-017-0531-x","article-title":"Efficacy of lomitapide in the treatment of familial homozygous hypercholesterolemia: results of a real-world clinical experience in Italy","volume":"34","author":"D'Erasmo","year":"2017","journal-title":"Adv Ther"},{"key":"2023070109284495400_ehad197-B53","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1016\/S0140-6736(12)61731-0","article-title":"Efficacy and safety of a microsomal triglyceride transfer protein inhibitor in patients with homozygous familial hypercholesterolaemia: a single-arm, open-label, phase 3 study","volume":"381","author":"Cuchel","year":"2013","journal-title":"Lancet"},{"key":"2023070109284495400_ehad197-B54","doi-asserted-by":"crossref","first-page":"381","DOI":"10.1186\/s13023-021-01999-8","article-title":"Long-term efficacy of lipoprotein apheresis and lomitapide in the treatment of homozygous familial hypercholesterolemia (HoFH): a cross-national retrospective survey","volume":"16","author":"D'Erasmo","year":"2021","journal-title":"Orphanet J Rare Dis"},{"key":"2023070109284495400_ehad197-B55","doi-asserted-by":"crossref","first-page":"832","DOI":"10.1093\/eurjpc\/zwab229","article-title":"Efficacy and safety of lomitapide in homozygous familial hypercholesterolaemia: the pan-European retrospective observational study","volume":"29","author":"D'Erasmo","year":"2022","journal-title":"Eur J Prev Cardiol"},{"key":"2023070109284495400_ehad197-B56","doi-asserted-by":"crossref","first-page":"332","DOI":"10.1161\/CIRCULATIONAHA.117.028208","article-title":"Long-term efficacy and safety of the microsomal triglyceride transfer protein inhibitor lomitapide in patients with homozygous familial hypercholesterolemia","volume":"136","author":"Blom","year":"2017","journal-title":"Circulation"},{"key":"2023070109284495400_ehad197-B57","doi-asserted-by":"crossref","first-page":"711","DOI":"10.1056\/NEJMoa2004215","article-title":"Evinacumab for homozygous familial hypercholesterolemia","volume":"383","author":"Raal","year":"2020","journal-title":"N Engl J Med"},{"key":"2023070109284495400_ehad197-B58","doi-asserted-by":"crossref","DOI":"10.1161\/circ.144.suppl_1.12756","article-title":"Long-term efficacy and safety of evinacumab in adult and adolescent patients with homozygous familial hypercholesterolemia","volume":"144","author":"Gaudet","year":"2021","journal-title":"Circulation"},{"key":"2023070109284495400_ehad197-B59","doi-asserted-by":"crossref","DOI":"10.1161\/circ.144.suppl_1.12066","article-title":"The long-term safety and efficacy of evinacumab in patients with homozygous familial hypercholesterolemia","volume":"144","author":"Raal","year":"2021","journal-title":"Circulation"},{"key":"2023070109284495400_ehad197-B60","doi-asserted-by":"crossref","first-page":"858","DOI":"10.1016\/j.jacl.2017.04.114","article-title":"Toward an international consensus-integrating lipoprotein apheresis and new lipid-lowering drugs","volume":"11","author":"Stefanutti","year":"2017","journal-title":"J Clin Lipidol"},{"key":"2023070109284495400_ehad197-B61","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1016\/j.jacl.2021.11.014","article-title":"Health-related quality of life in homozygous familial hypercholesterolemia: a systematic review and meta-analysis","volume":"16","author":"Alothman","year":"2022","journal-title":"J Clin Lipidol"},{"key":"2023070109284495400_ehad197-B62","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1016\/j.atherosclerosis.2018.01.034","article-title":"A nation-wide survey of patients with homozygous familial hypercholesterolemia phenotype undergoing LDL-apheresis in Turkey (A-HIT 1 registry)","volume":"270","author":"Kayikcioglu","year":"2018","journal-title":"Atherosclerosis"},{"key":"2023070109284495400_ehad197-B63","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1016\/j.atherosclerosis.2019.09.006","article-title":"Lipoprotein apheresis efficacy, challenges and outcomes: a descriptive analysis from the UK lipoprotein apheresis registry, 1989\u20132017","volume":"290","author":"Pottle","year":"2019","journal-title":"Atherosclerosis"},{"key":"2023070109284495400_ehad197-B64","doi-asserted-by":"crossref","first-page":"519","DOI":"10.1016\/S0021-9150(00)00371-3","article-title":"The rebound of lipoproteins after LDL-apheresis. Kinetics and estimation of mean lipoprotein levels","volume":"152","author":"Kroon","year":"2000","journal-title":"Atherosclerosis"},{"key":"2023070109284495400_ehad197-B65","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1016\/j.atherosclerosis.2009.06.010","article-title":"Efficacy criteria and cholesterol targets for LDL apheresis","volume":"208","author":"Thompson","year":"2010","journal-title":"Atherosclerosis"},{"key":"2023070109284495400_ehad197-B66","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1007\/s12265-011-9311-1","article-title":"Translational lessons from a case of combined heart and liver transplantation for familial hypercholesterolemia 20 years post-operatively","volume":"5","author":"Ibrahim","year":"2012","journal-title":"J Cardiovasc Transl Res"},{"key":"2023070109284495400_ehad197-B67","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1016\/j.jacl.2011.05.002","article-title":"Fatal cardiac atherosclerosis in a child 10 years after liver transplantation: a case report and a review","volume":"5","author":"El-Rassi","year":"2011","journal-title":"J Clin Lipidol"},{"key":"2023070109284495400_ehad197-B68","doi-asserted-by":"crossref","first-page":"504","DOI":"10.1016\/j.amjcard.2016.05.042","article-title":"Effects of liver transplantation on lipids and cardiovascular disease in children with homozygous familial hypercholesterolemia","volume":"118","author":"Martinez","year":"2016","journal-title":"Am J Cardiol"},{"key":"2023070109284495400_ehad197-B69","doi-asserted-by":"crossref","first-page":"3042","DOI":"10.1007\/s12325-022-02131-3","article-title":"Is liver transplant curative in homozygous familial hypercholesterolemia? A review of nine global cases","volume":"39","author":"Al Dubayee","year":"2022","journal-title":"Adv Ther"},{"key":"2023070109284495400_ehad197-B70","doi-asserted-by":"crossref","first-page":"121","DOI":"10.5551\/jat.RV17029","article-title":"Liver transplantation for homozygous familial hypercholesterolemia","volume":"26","author":"Ishigaki","year":"2019","journal-title":"J Atheroscler Thromb"},{"key":"2023070109284495400_ehad197-B71","doi-asserted-by":"crossref","first-page":"880","DOI":"10.1016\/j.jacl.2019.09.007","article-title":"Coronary artery disease in a child with homozygous familial hypercholesterolemia: regression after liver transplantation","volume":"13","author":"Cephus","year":"2019","journal-title":"J Clin Lipidol"},{"key":"2023070109284495400_ehad197-B72","doi-asserted-by":"crossref","first-page":"180","DOI":"10.1111\/j.1399-0012.2007.00764.x","article-title":"Liver transplantation in a subject with familial hypercholesterolemia carrying the homozygous p.W577R LDL-receptor gene mutation","volume":"22","author":"Schmidt","year":"2008","journal-title":"Clin Transplant"},{"key":"2023070109284495400_ehad197-B73","doi-asserted-by":"crossref","first-page":"456","DOI":"10.1136\/adc.73.5.456","article-title":"Liver transplantation for homozygous familial hypercholesterolaemia","volume":"73","author":"Revell","year":"1995","journal-title":"Arch Dis Child"},{"key":"2023070109284495400_ehad197-B74","doi-asserted-by":"crossref","DOI":"10.1542\/peds.2016-0740","article-title":"Progressive aortic stenosis in homozygous familial hypercholesterolemia after liver transplant","volume":"138","author":"Greco","year":"2016","journal-title":"Pediatrics"},{"key":"2023070109284495400_ehad197-B75","doi-asserted-by":"crossref","first-page":"1125","DOI":"10.5551\/jat.RV17065","article-title":"Advancements in the treatment of homozygous familial hypercholesterolemia","volume":"29","author":"Bajaj","year":"2022","journal-title":"J Atheroscler Thromb"},{"key":"2023070109284495400_ehad197-B76","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1016\/j.hfc.2021.07.008","article-title":"New frontiers in the treatment of homozygous familial hypercholesterolemia","volume":"18","author":"Cesaro","year":"2022","journal-title":"Heart Fail Clin"},{"key":"2023070109284495400_ehad197-B77","doi-asserted-by":"crossref","first-page":"975","DOI":"10.1161\/CIRCULATIONAHA.117.031335","article-title":"Reduced blood lipid levels with in vivo CRISPR-Cas9 base editing of ANGPTL3","volume":"137","author":"Chadwick","year":"2018","journal-title":"Circulation"},{"key":"2023070109284495400_ehad197-B78","doi-asserted-by":"crossref","first-page":"429","DOI":"10.1038\/s41586-021-03534-y","article-title":"In vivo CRISPR base editing of PCSK9 durably lowers cholesterol in primates","volume":"593","author":"Musunuru","year":"2021","journal-title":"Nature"},{"key":"2023070109284495400_ehad197-B79"},{"key":"2023070109284495400_ehad197-B80","doi-asserted-by":"crossref","first-page":"451","DOI":"10.1016\/j.atherosclerosis.2006.01.002","article-title":"Marked changes in plasma lipids and lipoproteins during pregnancy in women with familial hypercholesterolemia","volume":"189","author":"Amundsen","year":"2006","journal-title":"Atherosclerosis"},{"key":"2023070109284495400_ehad197-B81","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1016\/j.atherosclerosis.2016.10.018","article-title":"Lipoprotein apheresis is essential for managing pregnancies in patients with homozygous familial hypercholesterolemia: seven case series and discussion","volume":"254","author":"Ogura","year":"2016","journal-title":"Atherosclerosis"},{"key":"2023070109284495400_ehad197-B82","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1016\/j.transci.2015.11.008","article-title":"Severe dyslipidemia in pregnancy: the role of therapeutic apheresis","volume":"53","author":"Russi","year":"2015","journal-title":"Transfus Apher Sci"},{"key":"2023070109284495400_ehad197-B83","doi-asserted-by":"crossref","first-page":"370","DOI":"10.1097\/MOL.0000000000000790","article-title":"Management of familial hypercholesterolemia in pregnancy","volume":"32","author":"Graham","year":"2021","journal-title":"Curr Opin Lipidol"},{"key":"2023070109284495400_ehad197-B84","author":"US Food and Drug Administration"},{"key":"2023070109284495400_ehad197-B85","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1016\/j.atherosclerosissup.2014.07.006","article-title":"Daily life, experience and needs of persons suffering from homozygous familial hypercholesterolaemia: insights from a patient survey","volume":"15","author":"Bruckert","year":"2014","journal-title":"Atheroscler Suppl"},{"key":"2023070109284495400_ehad197-B86","doi-asserted-by":"crossref","first-page":"455","DOI":"10.1016\/j.jacl.2019.02.001","article-title":"Clinical management, psychosocial characteristics, and quality of life in patients with homozygous familial hypercholesterolemia undergoing LDL-apheresis in Turkey: results of a nationwide survey (A-HIT1 registry)","volume":"13","author":"Kayikcioglu","year":"2019","journal-title":"J Clin Lipidol"},{"key":"2023070109284495400_ehad197-B87","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1016\/j.atherosclerosis.2022.03.015","article-title":"Quality of life and coping in Dutch homozygous familial hypercholesterolemia patients: a qualitative study","volume":"348","author":"Mulder","year":"2022","journal-title":"Atherosclerosis"},{"key":"2023070109284495400_ehad197-B88","doi-asserted-by":"crossref","first-page":"556","DOI":"10.1177\/2047487319839179","article-title":"Impact of PCSK9 inhibitors on the quality of life of patients at high cardiovascular risk","volume":"27","author":"Cesaro","year":"2020","journal-title":"Eur J Prev Cardiol"},{"key":"2023070109284495400_ehad197-B89","doi-asserted-by":"crossref","first-page":"e6","DOI":"10.1016\/j.atherosclerosissup.2021.01.002","article-title":"Lipid clinics network. Rationale and design of the EAS global project","volume":"42","author":"Alieva","year":"2020","journal-title":"Atheroscler Suppl"},{"key":"2023070109284495400_ehad197-B90","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1038\/s41569-021-00645-x","article-title":"Improving clinical practice guidelines with implementation science","volume":"19","author":"Sarkies","year":"2022","journal-title":"Nat Rev Cardiol"},{"key":"2023070109284495400_ehad197-B91","doi-asserted-by":"crossref","first-page":"360","DOI":"10.1038\/s41569-019-0325-8","article-title":"Familial hypercholesterolaemia: evolving knowledge for designing adaptive models of care","volume":"17","author":"Watts","year":"2020","journal-title":"Nat Rev Cardiol"},{"key":"2023070109284495400_ehad197-B92","doi-asserted-by":"crossref","first-page":"953","DOI":"10.5551\/jat.63222","article-title":"Prospective Registry Study of Primary Dyslipidemia (PROLIPID): rationale and study design","volume":"29","author":"Tada","year":"2022","journal-title":"J Atheroscler Thromb"}],"container-title":["European Heart Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/eurheartj\/article-pdf\/44\/25\/2277\/50778062\/ehad197.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/eurheartj\/article-pdf\/44\/25\/2277\/50778062\/ehad197.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,10,16]],"date-time":"2024-10-16T15:52:58Z","timestamp":1729093978000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/eurheartj\/article\/44\/25\/2277\/7148157"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,5,2]]},"references-count":92,"journal-issue":{"issue":"25","published-online":{"date-parts":[[2023,5,2]]},"published-print":{"date-parts":[[2023,7,1]]}},"URL":"https:\/\/doi.org\/10.1093\/eurheartj\/ehad197","relation":{},"ISSN":["0195-668X","1522-9645"],"issn-type":[{"value":"0195-668X","type":"print"},{"value":"1522-9645","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2023,7,1]]},"published":{"date-parts":[[2023,5,2]]}}}